Clinical Trial Detail

NCT ID NCT02427581
Title Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Washington University School of Medicine
Indications

triple-receptor negative breast cancer

Therapies

Poly ICLC

Age Groups: adult

No variant requirements are available.